|
January 8, 2026
CLINICAL TRIAL SUPPLY MARKET: KEY INNOVATIONS, CHALLENGES, AND MARKET OUTLOOK, 2025
The clinical trial supply chain is experiencing its profound transformation in a decade. The increasing number of decentralized trials, personalized medicines, and the increased global patient recruitment increased pressure on clinical trial supply leaders to deliver speed, precision, and compliance in this volatile environment. The shift to patient-centric supply from site-centric supply, the growth of temperature-sensitive products, and increasingly complex regulatory pathways force sponsors and CROs to reappraise traditional models. In 2025, success is dependent upon real-time visibility, digital intelligence, and robust networks capable of supporting high-variability protocols across diverse geographies. We have spotlighted the most influential trends shaping trends in the clinical trial supply landscape below, informed by current industry research and global thought leadership.
Our latest research indicates that the Clinical Trial Supplies Market, spanning from manufacturing, packaging, to comparator sourcing, distribution, and long-term storage, was valued at $4.85 billion in 2024. With accelerating biopharma innovation, decentralized trial models, integration of digital technologies, and growing demand for complex and temperature-sensitive therapies (personalized medicines & biologics), the market is on track to reach $8.18 billion by 2030, growing at CAGR of 8.9% during the forecast period (2025-2030). In this article, we examine the trends most likely to shape the clinical-trial supply industry.
The Technology Ecosystem Enabling the Future of Global and Decentralized Trials
The clinical trial supply ecosystem is rapidly evolving, driven by emerging digital and automation technologies that can significantly improve visibility, control, and compliance across global operations. The introduction of key technologies, like serialization and track-and-trace systems, has provided a way for sponsors to ensure product authentication throughout the entire process; to fight counterfeit products; and to meet increasingly stringent regulatory standards. In addition, Interactive Response Technologies (IRT, IVR, IWR) have been integral to randomization, drug assignment, and inventory management, reducing the number of manual errors and allowing for adaptive trial designs. Cold-chain and temperature monitoring solutions are now crucial for maintaining oversight of biologics, cell & gene therapies, and other temperature-sensitive products via real-time sensor information and Cloud-connected dashboard solutions.
Complementary and adjacent technologies are amplifying these core capabilities, creating a more predictive, automated, and resilient supply chain. The increasing use of Artificial Intelligence (AI) and Machine Learning (ML) provides a more predictable, automated, and robust supply chain, along with blockchain, that increase transparency and maintain data security between multiple supply chain partners. Also, adjacent innovations (such as cryopreservation, advanced storage technologies to meet the needs of next-generation therapies, and robotic technology within warehousing/distribution) are being used to enhance throughput and reduce errors by humans. Together as a technology platform, these innovations will enable the contracting organizations and sponsors to manage the increasing operational complexity being created by the development and use of multinational and decentralized clinical trials while providing speed, reliability, and improved patient safety.
Rising Trial Complexity and Tech Adoption Drive Growth Across Logistics and Comparator Sourcing
Clinical trial supplies market is categorized into services, logistics & distribution; storage & retention, packaging, labeling, and blinding; manufacturing, comparator sourcing, and other services. Logistics & distribution are integral components of the clinical trial supplies market. As clinical trials continue to become more globalized and decentralized, the logistics and distribution services continue to increase as they see an increased need for direct-to-patient deliveries, fast small volume shipments and real time tracking associated with temperature control. Further, the increasing use of biologics and advanced therapies, there is a need to use temperature-controlled transportation with a stronger chain of custody processes. Sponsors are increasingly using specialized logistics partners to handle cross-border complexities and help to reduce timelines and guarantee product integrity, thus driving continued growth in this segment.
Additionally, Comparator Sourcing has grown to become the fastest-growing category of services due to the growing number of head-to-head comparisons of drugs, combination therapy study populations, and competitive benchmarking needs across various areas, including oncology, neurology, immunology, and rare diseases. It is increasingly difficult to find and obtain genuine and compliant comparators due to the global shortage of products, pricing disparities between regions, and the need for stringent documentation. Sponsors are therefore increasingly using specialized sourcing partners for access to authenticated products, risk management of product supply, and compliance. This trend, in combination with the growing pipelines of new biologics, continues to drive demand for comparator sourcing services.
Clinical trial supplies market landscape, by phase
Based on phases, the clinical trial supplies market is segmented into phase I, phase II, phase III, phase IV and Phase BA/BE. Phase III remains the largest clinical trial supplies segment, as this stage requires the largest number of patients enrolled into clinical trials compared to the other phases and has the widest geographical distribution of patients as well. Phase III also has the highest volume of investigational products needed during this phase. Sponsors choose to use an external supply partner(s) to handle all aspects of a multi-regional supply chain. In addition to supporting the logistical requirements of the sponsors, these external supply partners must ensure all products are shipped according to strict regulations established by the FDA. The increased activity in late-phase development programs (specifically oncology, immunology, and rare diseases) will continue to create additional complexities in the supply chain, resulting in higher costs and making phase III the largest contributor to overall market demand for clinical trial supplies.
Innovation in Biologic Drug Modalities Drives New Clinical Supply Priorities
Based on the modalities, the market for clinical trial supplies is divided into three categories: biologic drugs, small-molecule drugs, and medical devices. Biologics are the fastest-growing segment, driven by the increase in cell and gene therapies, immunotherapies, monoclonal antibody (mAb) development, and personalized medicine. Biologics have unique supply chain needs associated with ultra-cold storage, temperature-controlled shipping, an advanced chain of custody, and smaller batches at the patient level. Many sponsors do not have all these capabilities in place; therefore, as many biopharma pipelines shift from product types to high-value, personalized, or immunotherapy-based products, there is an increase in the complexity of clinical supply chain requirements, which is responsible for the rapid growth and development of biologics.
Companies such as Lonza, Catalent, and Samsung Biologics now play a central role in supporting clinical trials by providing true end-to-end supply solutions. Their integrated offerings spanning formulation, fill–finish, packaging, storage, and global distribution allow sponsors to simplify complex supply chains, accelerate study start-up, and maintain consistent product availability across geographies. WuXi Biologics is another strong example: its recent facility expansions across the US, Europe, and China have strengthened its global footprint, enabling pharma companies to scale clinical-stage manufacturing more efficiently and manage multi-regional trials with greater reliability.
Leading Global Players Shaping the Clinical Trial Supplies Ecosystem
The clinical trial supplies industry is influenced by several service providers at global and regional level. These entities provide decentralized as well as integrated offerings. Key players are Thermo Fisher Scientific (US), Novo Holdings A/S (Denmark), Marken (a UPS company, US), Eurofins Scientific (France), Piramal Pharma Solutions (India), PRA Health Sciences (US), Parexel International (US), Biocair (UK), Almac Group (UK), Sharp Services (US), PCI Pharma Services (US), and Lonza Group (Switzerland), among others. These organizations help sponsors simplify complex trial operations with flexible geographic coverage, on-demand manufacturing, specialized packaging and labeling, and strong distribution capabilities.
These companies actively seek collaborations, strategic partnerships, acquisitions, and service expansions to strengthen their market position and expand their global reach. Recent initiatives demonstrate the industry's focus on enhancing supply chain resilience, improving decentralization capabilities, and supporting the growing number of multi-country and late-stage clinical trials.
In July 2024, Catalent (acquired by Novo Holdings) invested USD 25 million in expanding its clinical supply facility in Schorndorf, Germany, providing comprehensive clinical supply services, including packaging, storage, and distribution.
- In September 2024, PCI Pharma invested USD 65 million in expanding the clinical and establishing a new Center of Excellence for advanced drug delivery and drug-device combination product assembly and packaging in Rockford, Illinois.
- In April 2024. Parexel International (MA) Corporation (US) and Palantir (US) collaborated to accelerate clinical data delivery and power clinical outcomes for patients.
- In July 2023, Thermo Fisher Scientific entered into a collaboration with NMQF, an independent non-profit organization dedicated to research and education. This collaboration, facilitated through NMQF’s Alliance for Representative Clinical Trials (ARC), aims to improve the inclusion of historically underserved patient groups in clinical research.
- In March 2025, Icon PLC (Ireland) and Mural Health Technologies Inc. (US) partnered to enhance participant and site experience in clinical trials.
CONCLUSION
Conclusively, the clinical trial supplies industry is experiencing a robust transition led by the expansion of drug development activities into new therapy areas, decentralized models, and geographies. There is heavy dependence of sponsors on specific supply partners to manage increased operational complexities, including sourcing comparator products, coordinating a multi-country supply chain, and supporting highly regulated supply chains associated with advanced therapies. Sponsors are increasingly moving to third-party supply partners that provide advanced technology solutions, such as AI-based systems, real-time tracking of supplies, tracking and tracing of product serialization, robotic systems for supply chain operations and blockchain-enabled transparency into the movement of product throughout the supply chain. With service providers broadening their capabilities such as, enhanced supply resilience, assured compliance, and patient-centric trial delivery models support through partnerships, investments, and strategic initiatives, the industry is steadily moving toward more connected and adaptive supply solutions. These developments collectively position clinical trial supply networks to better support future research needs, improve reliability, and enable more efficient delivery of investigational products to participants worldwide.
Contact:
Priyanka Tiwari
priyanka.tiwari@marketsandmarkets.com
MarketsandMarkets™ INC.
Source: MarketsandMarkets https://www.marketsandmarkets.com/
"Reproduced with permission - MarketsandMarkets™"
MarketsandMarkets™
Back to ...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS: HIV/AIDS News Archive
|
